Complex regional pain syndrome patient immunoglobulin M has ... : PAIN

Last updated: 04-11-2020

Read original article here

Complex regional pain syndrome patient immunoglobulin M has ... : PAIN

aPalo Alto Veterans Institute for Research, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, United States
bDepartment of Anesthesia, Stanford University School of Medicine, Stanford, CA, United States
cAnesthesiology Service, Veterans Affairs Palo Alto Health Care System Palo Alto, CA, United States
dDepartment of Neurology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
ePain Research Institute, University of Liverpool, Liverpool, United Kingdom
fThe Walton Centre NHS Foundation Trust, Liverpool, United Kingdom
gDepartment of Neurology, Justus Liebig University, Giessen, Germany
*Corresponding author. Address: PAVIR (115P), Veterans Affairs Palo Alto Health Care System, 3801 Miranda Ave, Palo Alto, CA 94304, United States. Tel.: 650-207-3733. E-mail address: wkingery@stanford.edu (W. Kingery).
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site ( www.painjournalonline.com ).
Abstract
In Brief
It has been proposed that complex regional pain syndrome (CRPS) is a post-traumatic autoimmune disease. Previously, we observed that B cells are required for the full expression of CRPS-like changes in a mouse tibia fracture model and that serum immunoglobulin M (IgM) antibodies from fracture mice have pronociceptive effects in muMT fracture mice lacking B cells. The current study evaluated the pronociceptive effects of injecting CRPS patient serum or antibodies into muMT fracture mice by measuring hind paw allodynia and unweighting changes. Complex regional pain syndrome serum binding was measured against autoantigens previously identified in the fracture mouse model. Both CRPS patient serum or IgM antibodies had pronociceptive effects in the fracture limb when injected systemically in muMT fracture mice, but normal subject serum and CRPS patient IgG antibodies had no effect. Furthermore, CRPS serum IgM antibodies had pronociceptive effects when injected into the fracture limb hind paw skin or intrathecally in the muMT fracture mice. Early (1-12 months after injury) CRPS patient (n = 20) sera were always pronociceptive after systemic injection, and chronic (>12 months after injury) CRPS sera were rarely pronociceptive (2/20 patients), while sera from normal subjects (n = 20) and from patients with uncomplicated recoveries from orthopedic surgery and/or fracture (n = 15) were never pronociceptive. Increased CRPS serum IgM binding was observed for keratin 16, histone 3.2, gamma actin, and alpha enolase autoantigens. We postulate that CRPS patient IgM antibodies bind to neoantigens in the fracture mouse skin and spinal cord to initiate a regionally restricted pronociceptive complement response potentially contributing to the CRPS disease process.
Complex regional pain syndrome patient IgM-mediated autoimmunity supports nociceptive sensitization in the mouse fracture model.
1. Introduction
Complex regional pain syndrome (CRPS) is an enigmatic syndrome that typically develops after limb injury or surgery and presents with distal limb nociceptive, vascular, and bone changes that exceed the expected clinical course of the inciting injury, frequently resulting in significant motor impairment and disability. 43 Distal limb fracture is the most common cause of CRPS, 9,37 and we have developed a tibia fracture rodent model closely resembling CRPS. 3 Distal tibia fractured rats and mice casted for 3 to 4 weeks develop hind paw allodynia, unweighting, warmth, edema, increased spontaneous protein extravasation, and regional periarticular bone loss. 17 The fracture CRPS model has been successfully used to study the effects of fracture on neuropeptide signaling, 17,19,48,50 the sympathetic nervous system, 25 mast cell infiltration, 27 keratinocyte 41,48,51 and microglia 29,40 inflammatory mediator (IL-1, IL-6, tumor necrosis factor [TNF], chemokine [cc-motif] ligand 2 [CCL2], and nerve growth factor [NGF]) production, 10,26,30,34,35,49 and other CRPS-related phenomena. 16
Accumulating evidence suggests that CRPS may involve both autoinflammatory and autoimmune components. 8,12 Previously, we investigated the effects of B-cell depletion in the fracture model using anti-CD20 antibodies and in muMT fracture mice lacking both B cells and immunoglobulin and observed that (1) wildtype (WT) mice treated with intravenous anti-CD20 antibody had virtually no mature B cells and exhibited attenuated hind paw allodynia, unweighting, warmth, and edema, (2) muMT mice had attenuated nociceptive and inflammatory changes at 3 weeks after fracture, (3) IgM-containing immune complexes were deposited in skin and sciatic nerve at 3 weeks after fracture in WT mice but not in muMT fracture mice, and (4) complement system membrane attack complex deposition in skin and sciatic nerve after fracture was partially reversed by anti-CD20 treatment. 28 Furthermore, when serum or IgM antibodies collected from WT fracture mice were injected into muMT fracture mice, they gradually developed increased hind paw allodynia and unweighting, peaking at 7 days and resolving by 14 days after injection, consistent with the half-life of IgM. 18 Serum from nonfractured WT mice or IgG from fractured WT mice had no pronociceptive effects in the muMT fracture mice. IgM antibody levels gradually increased in the WT mouse fracture limb hind paw skin, sciatic nerve, and corresponding lumbar cord, peaking at 12 to 18 weeks after fracture and then declining to baseline levels at 23 weeks after fracture, consistent with the time course of postfracture nociceptive sensitization.
Based on these experiments, we postulated that fracture induced the regional expression of novel antigens in the mouse fracture limb hind paw skin and corresponding spinal cord, and that CRPS patient autoantibodies might be capable of binding to those antigens and initiating a antibody–antigen–complement response resulting in sensitization of nociceptive neurons. 22 The current study tested the hypothesis that the systemic injection of serum antibodies from CRPS patients can induce regionally restricted pain behaviors in muMT B-cell–deficient fracture mice and then identified the immunoglobulin isotype responsible for these pronociceptive effects. Additional experiments tested the hypothesis that CRPS autoantibodies can induce pronociceptive effects after injection in hind paw skin or intrathecal injection in muMT fracture mice. Finally, CRPS patient serum binding was measured against autoantigens previously identified in the fracture model.
2. Materials and methods
2.1. Subjects and clinical data collection
The study protocols were approved by the respective local institutional review boards in accordance with the Declaration of the World Medical Association. Four cohorts of subjects were evaluated for pronociceptive serum effects in muMT fracture mice: (1) normal control subjects (n = 20), (2) early CRPS (n = 20), (3) chronic CRPS (n = 20), and (4) orthopedic limb trauma patients without CRPS (n = 15). The normal control subject sera were collected by a commercial company using our serum processing protocol, and all control subjects were tested negative for HIV and HCV antibodies and nonreactive for hepatitis B surface antigen, human immunodeficiency virus 1 RNA, hepatitis B DNA, hepatitis C RNA, and sexually transmitted diseases (BioreclamationIVT, Westbury, NY). All early and chronic CRPS patient sera were collected in Mainz and Giessen Germany (by F.B., F.L.E., M.H., and H.H.K.) except for 12 chronic CRPS patient sera that were collected in Liverpool United Kingdom (by A.G.). The orthopedic trauma without CRPS patient sera were collected in Palo Alto California (by P.S.). All patient subjects were enrolled after giving written informed consent. Inclusion criteria for the early CRPS cohort included meeting the Budapest clinical scientific criteria for CRPS 20 at the time of serum collection and a duration of CRPS between 1 and 12 months after injury. Inclusion criteria for the chronic CRPS cohort included meeting the Budapest criteria and a duration of CRPS greater than 12 months after injury. The inclusion criteria for the resolved CRPS cohort were that the patients met the Budapest CRPS criteria when the initial serum samples were collected but when the patients were re-evaluated 2 or more years later for repeat serum collection, they no longer met CRPS diagnostic criteria. The inclusion criteria for the orthopedic trauma without CRPS cohort were that patients must be 1 to 12 months after orthopedic surgery and/or fracture and fail to meet the Budapest clinical diagnostic criteria for CRPS at the time of serum collection. Patient demographics and clinical data were recorded, including age, sex, CRPS duration and etiology, involved limb, pain medications, numerical 11-point (0-10, no pain to the worst pain possible) pain scale, and allodynia. Allodynia was tested by applying 3 to 4 light strokes with a small brush to the affected skin and asking patients if this evoked a normal or abnormal sensation. If the sensation was described as abnormal, the patient was asked to give a qualitative description of the sensation. Descriptions of the brushing as uncomfortable, scratchy, or painful were regarded as allodynia.
2.2. Animals
These experiments were approved by the Veterans Affairs Palo Alto Health Care System Institutional Animal Care and Use Committee (Palo Alto, CA) and followed the animal subject guidelines of the International Association for the Study of Pain. Three-month-old male muMT mice lacking mature B cells and immunoglobulin, on a C57BL/6J congenic background (#002288; Jackson Laboratory, Bar Harbor, ME), were used in these experiments (n = 330). The animals were housed 4 per group under pathogen-free conditions with soft bedding and were given food and water ad libitum, with a 12:12 light:dark cycle. During the experimental period, the animals were fed Teklad laboratory rodent diet 2018 (Harlan Laboratories, Indianapolis, IN), which contains 1.0% calcium, 0.7% phosphorus, and 1.5 IU/g vitamin D3, and were kept under standard conditions with a 12-hour light–dark cycle. Data collection was conducted blind to group assignment. All animal and biochemical experiments described in these studies were performed in Palo Alto California (by T.-Z.G., T.W., M.T., and W.-W.L.).
2.3. Surgery
The fracture model was performed in 3-month-old male mice as previously described. 19 Under isoflurane anesthesia, a hemostat was used to make a closed fracture of the right tibia just distal to the middle of the tibia. The hind limb was then wrapped in casting tape (Delta-Lite; BSN Medical, Hamburg, Germany), so the hip, knee, and ankle were all fixed. After fracture and casting, the mice were given subcutaneously 2 days of buprenorphine (0.1 mg/kg) and enrofloxacin (5 mg/kg) as well as 1.0 mL of normal saline. At 3 weeks after surgery, the mice were anesthetized with isoflurane and the cast removed. All mice had union at the fracture site by manual inspection.
2.4. Hind paw nociceptive testing
Mechanical allodynia was assayed using nylon von Frey filaments according to the “up-down” algorithm as previously described. 6 The mice were placed on wire mesh platforms in clear cylindrical plastic enclosures 10 cm in diameter and 40 cm in height, and after 15 minutes of acclimation, von Frey fibers of sequentially increasing stiffness were applied against the hind paw plantar skin at approximately midsole, taking care to avoid the tori pads, and pressed upward to cause a slight bend in the fiber and left in place for 5 seconds. Withdrawal of or licking the hind paw after fiber application was scored as a response. When no response was obtained, the next stiffest fiber in the series was applied to the same paw; if a response was obtained, a less stiff fiber was applied. Testing proceeded in this manner until 4 fibers had been applied after “negative + positive or positive + negative” response. Hind paw testing was performed bilaterally. Estimation of the mechanical withdrawal threshold by data fitting algorithm permitted the use of parametric statistics for analysis. 32 These data were analyzed as the difference between the fracture side and the contralateral untreated side; thus, a negative value represents a reduction in the fracture hind paw withdrawal threshold.
An incapacitance device (IITC Life Science, Woodland Hills, CA) was used to measure bilateral hind paw weight-bearing. The mice were manually held in a vertical position over the apparatus with the hind paws resting on separate metal scale plates, and the entire weight of the mouse was supported on the hind paws. The duration of each measurement was 6 seconds, and 6 consecutive measurements were taken at 10-second intervals. All 6 readings were averaged to calculate the bilateral hind paw weight-bearing values. Right hind paw (fracture side) weight-bearing data were analyzed as a ratio between the right hind paw weight and the average of right and left hind paw values ((2R/(R + L)) × 100%); thus, a value less than 100% represents a decrease in weight-bearing in the fracture limb.
2.5. Hind paw temperature testing
The temperature of the bilateral hind paws was measured using a fine wire thermocouple (Omega Engineering, Norwalk, CT) applied to the paw skin, as previously described. 30 The investigator held the wire using an insulating Styrofoam block. Three sites were tested over the dorsum of the hind paw: the space between the first and second metatarsals (medial), the second and third metatarsals (central), and the fourth and fifth metatarsals (lateral). After a site was tested in 1 hind paw, the same site was immediately tested in the contralateral hind paw. The testing protocol was medial dorsum right then left, central dorsum right then left, lateral dorsum right then left, medial dorsum left then right, central dorsum left then right, and lateral dorsum left then right. The 6 measurements for each hind paw were averaged for the mean temperature. These data were analyzed as the difference between the fracture side and the contralateral untreated side; thus, a positive value represents increased temperature in the fracture paw.
2.6. Hind paw thickness testing
A laser sensor technique was used to determine the dorsal–ventral thickness of the bilateral hind paws, as we have previously described. 30 For laser measurements, each mouse was briefly anesthetized with isoflurane and then held vertically, so the hind paw rested on a table top below the laser. The paw was gently held flat on the table with a small metal rod applied to the top of the ankle joint. Using optical triangulation, a laser with a distance-measuring sensor was used to determine the distance to the table top and to the top of the hind paw at the midpoint of the third metatarsal, and the difference was used to calculate the dorsal–ventral paw thickness. The measurement sensor device used in these experiments (Limab, Goteborg, Sweden) has a measurement range of 200 mm with a 0.01-mm resolution. These data were analyzed as the difference between the fracture side and the contralateral untreated side; thus, a positive value represents increased paw thickness in the fracture paw.
2.7. Complex regional pain syndrome serum and immunoglobulin injection experiments in the fracture mouse complex regional pain syndrome model
This experiment examined the pronociceptive (hind paw mechanical allodynia and unweighting) and inflammatory (hind paw warmth and edema) effects of early (1-12 months after injury) CRPS patient serum after intraperitoneal injection into 3-week postfracture muMT mice ( Fig. 1 ). After clinical evaluation, CRPS patient blood was collected in 10-mL red top tubes and left undisturbed at room temperature for 60 minutes to allow clotting, then refrigerated overnight at 4°C, and then the blood samples were centrifuged at 2,200g for 20 minutes at 4°C, and the serum supernatants were aliquoted and frozen at −80°C. The muMT mice underwent baseline behavioral testing (measuring hind paw von Frey allodynia, unweighting, warmth, and edema), and then, under isoflurane anesthesia, the right distal tibia was fractured and casted. At 3 weeks after fracture, the casts were removed, and behavioral testing was repeated the next day, and then, the mice were injected with the CRPS patient serum or with normal control subject serum (500 μl, i.p.). Further behavioral testing was performed at 1, 5, 7, 9, 14, and 21 days after injection. Each CRPS patient (n = 5) or control (n = 5) serum was injected into 3 different muMT fracture mice, and the test results were averaged for each subject.
Figure 1.:
Complex regional pain syndrome patient serum and IgM had pronociceptive effects in B-cell–deficient fracture mice. At 3 weeks after tibia fracture and casting (FX), muMT mice lacking B cells and IgM exhibited unilateral hind paw von Frey allodynia (A) and unweighting (B). After intraperitoneal injection of early (1-12 months after injury) CRPS patient serum (0.5 mL, i.p.) or IgM (500 μg/1 mL, i.p.) into 3-week post-FX muMT mice, the mice gradually developed increased allodynia and unweighting over the ensuing week, and consistent with the 6 days half-life of IgM, these pronociceptive effects resolved by 2 weeks after injection. The pronociceptive effects of the CRPS serum were restricted to the FX limb, and there was no serum effect on post-FX hind paw edema or warmth (data not shown). No pronociceptive effects were observed after intraperitoneal injection of early CRPS patient IgG (5 mg/1 mL, i.p.) or after injection of control subject serum (0.5 mL, i.p.) in 3-week post-FX mice. Measurements for (A) represent the difference between the FX side and contralateral paw; thus, a negative value represents a decrease in mechanical withdrawal thresholds on the affected side. Measurements for (B) represent weight-bearing on the FX hind limb as a ratio to half of the total bilateral hind limb loading; thus, a percentage lower than 100% represents hind paw unweighting. A 2-way repeated-measures analysis of variance was used to test the effects of each treatment group on the dependent variables over time, using a Sidak correction test for post hoc contrasts. Data are expressed as mean values ± SEM, n = 5 patients per cohort, and each patient's serum or immunoglobulin was injected into 3 mice for a total n of 15 mice. #P < 0.05, ##P < 0.01, and ###P < 0.001, ####P < 0.0001 for each injection cohort vs the control serum treatment group. 3wkFX, 3 weeks after fracture; BL, baseline; CRPS, complex regional pain syndrome; FX, fracture; MuMT, mice lacking B cells.
Another experiment was designed to identify the immunoglobulin isotype responsible for the pronociceptive effects of early CRPS patient serum in 3-week postfracture muMT mice ( Fig. 1 ). IgM was extracted from the CRPS serum using a polypropylene column (BioRad, Hercules, CA) prepacked with POROS CaptureSelect IgM Affinity Matrix (Thermo Fisher Scientific, Leiden, the Netherlands). The bound IgM was eluted using 100-mM glycine pH 3, then the elute pH was adjusted to 7.4 using 1M Tris pH 8.0, and then Slide-A-Lyzer Dialysis Cassettes (10K MWCO, Life Technologies, Carlsbad, CA) were used to remove glycine from protein and the IgM quantified using a NanoDrop ND-1000 UV-Vis spectrophotometer (NanoDrop Technologies, Wilmington, DE). The dose of IgM used in the current study (500 μg, i.p.) is 20% less than the amount of IgM that would be predicted in 500 μl of adult human serum. 13 IgG was extracted from CRPS serum using a POROS CaptureSelect IgG Affinity Matrix (Thermo Fisher Scientific) with the pH adjusted to 7.4 using 1M Tris pH 8.0, and then, Slide-A-Lyzer Dialysis Cassettes (10K MWCO; Life Technologies) were used to remove glycine from protein, and IgG quantified using a NanoDrop ND-1000 UV-Vis spectrophotometer (NanoDrop Technologies). The dose of IgG injected in the current study (5 mg, i.p.) is consistent with, and at least equal to, the IgG dose injected with 500 μl of adult human serum 13 ; thus, we were confident that a negative response to 5 mg of CRPS IgG would be physiologic and not attributable to insufficient dosage.
To test the pronociceptive effects of the immunoglobulin isotypes, muMT mice underwent baseline nociceptive behavioral testing (measuring hind paw von Frey allodynia and unweighting), and then, under isoflurane anesthesia, the right distal tibia was fractured and casted. At 3 weeks after fracture, the casts were removed, and the next day, nociceptive behavioral testing was repeated, and the mice were injected with either IgM (500 μg, i.p.) or IgG (5 mg, i.p.) from early CRPS patients (n = 5). Further nociceptive behavioral testing was performed at 1, 7, 14, and 21 days after injection. Each CRPS patient's IgM or IgG was injected into 3 different muMT fracture mice, and the test results were averaged for each subject's immunoglobulin isotype.
2.8. Complex regional pain syndrome IgM intrathecal and intraplantar injection experiments in fracture mice
In this experiment, the pronociceptive effects of injecting early (1-12 months after injury) CRPS patient IgM into the lumbar spinal fluid or hind paw plantar skin of fracture mice were evaluated ( Fig. 2 ). Under isoflurane anesthesia, muMT mice underwent right distal tibia fracture and casting, and at 3 weeks after fracture, the casts were removed, and the next day, behavioral testing (measuring hind paw von Frey allodynia, unweighting, warmth, and edema) was performed, then the mice were injected with pooled IgM (5 μg/ul intrathecal or 7.8 μg/ul, intraplantar) from early CRPS patients (n = 8) or normal control subjects (n = 8). Further behavioral testing was performed at 0.5, 1, 3, 6, and 24 hours after injection and at 7 days after injection.
Figure 2.:
Complex regional pain syndrome patient IgM had pronociceptive effects in both the spinal cord and skin of B-cell–deficient fracture mice. After intrathecal injection of early (1-12 months after injury) CRPS patient IgM (5 μg/5 μl, i.t.) into 3-week postfracture (FX) muMT mice, the mice rapidly developed increased von Frey allodynia (A) and unweighting (B) within 30 minutes that resolved over the ensuing 6 hours. The pronociceptive effects of the intrathecal IgM injection were restricted to the FX limb, and there were no pronociceptive effects when early CRPS IgM was injected intrathecally into nonfracture wildtype mice. No pronociceptive effects were observed after intrathecal injection of control subject IgM. Likewise, after intraplantar injection of early CRPS patient IgM (7.8 μg/5 μl, i.pl.) into the fracture hind limb paw of 4-week post-FX muMT mice, the mice rapidly developed increased von Frey allodynia (C) and unweighting (D) within 1 hour that resolved over the ensuing 6 hours. The pronociceptive effects of the intraplantar IgM injection were restricted to the FX limb, and there was no IgM effect on post-FX hind paw edema or warmth (data not shown). No pronociceptive effects were observed after intraplantar injection of control subject IgM. Furthermore, there were no pronociceptive effects after intraplantar injection of early CRPS IgM in nonfracture wildtype mice. A 2-way repeated-measures analysis of variance was used to test the effects of each treatment group on the dependent variables over time, using a Sidak correction test for post hoc contrasts. Data are expressed as mean values ± SEM, n = 7 (IgM was eluted from sera pooled from 8 early CRPS patients or 8 control subjects and injected intrathecally or intraplantarly into 7 mice per cohort). #P < 0.05, ##P < 0.01, and ###P < 0.001 for the CRPS IgM cohort vs the control IgM treatment group, *P < 0.05 and ***P < 0.001 for each postinjection time point vs its respective baseline (eg, 3wkFX or 4wkFX). 3wkFX, 3 weeks after fracture; 4wkFX, 4 weeks after fracture; CRPS, complex regional pain syndrome; FX, fracture; MuMT, mice lacking B cells; FX, fracture; NonFX, nonfractured mice; WT, wildtype mice.
2.9. Testing sera from control subjects, early complex regional pain syndrome patients, chronic complex regional pain syndrome patients, and limb trauma patients without complex regional pain syndrome for pronociceptive effects in fracture mice
This experiment examined the pronociceptive effects (hind paw mechanical allodynia and unweighting) of injecting sera from normal control subjects (n = 20), early (1-12 months after injury) CRPS patients (n = 20), chronic (>12 months after injury) CRPS patients, and orthopedic limb trauma patients without CRPS (n = 15) into 3-week postfracture muMT mice ( Fig. 3 ). After clinical evaluation, patient blood was collected and processed for sera. All sera were processed as previously described, except for 12 chronic CRPS patients whose sera were collected in orange top tubes containing a clotting activator and a gel-separator and were processed within 30 minutes by centrifuging at 2,000g for 10 minutes. Under isoflurane anesthesia, muMT mice underwent right distal tibia fracture and casting. At 3 weeks after fracture, the casts were removed, and behavioral testing (hind paw allodynia and unweighting) was performed the next day, and then, the mice underwent intraperitoneal injection with human sera (500 μl, i.p.). Further behavioral testing was performed at 7 days after injection (time of peak pronociceptive effects, Fig. 1 ). Each patient's serum was injected into 3 different muMT fracture mice, and the test results were averaged for each subject. A significant (25%) reduction in hind paw von Frey withdrawal thresholds and/or hind paw weight-bearing at day 7 after fracture was considered indicative of nociceptive sensitization.
Figure 3.:
All early CRPS patient sera were pronociceptive in B-cell–deficient fracture mice. Serum was collected from 4 different groups of subjects normal control subjects (controls, n = 20), early (1-12 months after injury) CRPS patients (early CRPS, n = 20), chronic (>12 months after injury) CRPS patients (chronic CRPS, n = 20), and orthopedic trauma patients without CRPS (1-12 months after injury, trauma no CRPS, n = 15). At 3 weeks after tibia fracture and casting in muMT mice, the cast was removed, and the next day, the mice underwent hind paw von Frey allodynia (A) and unweighting (B) testing, then each subject's serum was intraperitoneally injected into 3 fracture mice (0.5 mL per mouse, i.p.), and then, the mice were retested at 1 week after injection (time point of peak pronociceptive effect, Fig. 1 ). The change in von Frey threshold differences and percent weight-bearing between the 3-week postfracture testing and day 7 postinjection testing were calculated for each mouse and averaged for the 3 mice injected with each subject's serum. An increase of greater than 25% (red line) in allodynia or unweighting was considered pronociceptive. Early CRPS patient serum usually (18/20) caused increased hind paw allodynia (A) and always increased hind limb unweighting in fracture mice (B). Only 2 of the 20 chronic CRPS sera caused increased allodynia, and none of the chronic CRPS sera changed unweighting in fracture mice. Injection of sera from control subjects or orthopedic trauma patients without CRPS had no effects on allodynia and unweighting. A 1-way repeated-measures analysis of variance was performed followed by a Sidak correction test for post hoc contrasts. Data are expressed as mean values ± SD. ***P < 0.001 for vs controls, ###P < 0.001 vs early CRPS. CRPS, complex regional pain syndrome.
2.10. Dot blot assays for screening complex regional pain syndrome IgM binding reactivity to potential autoantigens
Recombinant human proteins were purchased for dot blotting to measure specific IgM binding reactivity in the sera of normal controls, early CRPS patients, chronic CRPS patients, and resolved CRPS patients. The 9 protein candidates initially screened included (1) alpha enolase, (2) gamma actin, (3) glutamate ionotropic receptor delta type subunit 2 (GRID2), (4) eukaryotic translation elongation factor 1 alpha 1 (EEF1A1), (5) beta tubulin, (6) interleukin 1 receptor–associated kinase 1 (IRAK1), and (7) synaptotagmin were all obtained from Abcam, Burlingame, CA, (8) keratin 16 (Novus Biologicals, Centennial, CO), and (9) histone 3.2 (New England Biolabs, Ipswich, MA). Full length proteins were used whenever commercially available. These potential autoantigens were selected based on results of our previous liquid chromatography–tandem mass spectroscopy studies in fracture mouse skin. 44 Each recombinant protein (2 μl) was applied to a nitrocellulose membrane and incubated for 1 hour with human sera (1:1000 dilution in TPBS) followed by 1 hour incubation with anti-human IgM-Dylight800 secondary antibody (1:10,000 dilution, Thermo Fisher Scientific, Waltham, MA). The signals were detected using Odyssey Near-Infrared Fluorescence Imaging System and quantified using Image Studio Lite (LI-COR Biosciences, Lincoln, NE).
2.11. Statistical analysis
Statistical analysis was performed using a two-way repeated-measures analysis of variance (ANOVA) ( Figs. 1 and 2 ) or a 1-way ANOVA ( Fig. 3 ) with the Holm–Sidak multiple comparisons test for post hoc contrasts. Figure 4 data were not normally distributed, so statistical analysis was performed using a Kruskal–Wallis 1-way ANOVA followed by Dunn's multiple comparisons tests for post hoc contrasts. Data are presented as the mean ± SEM ( Figs. 1 and 2 ) or scatter plots ( Figs. 3 and 4 ), and differences are considered significant at a P value less than 0.05 (Prism 5, GraphPad Software, San Diego, CA).
Figure 4.:
Early CRPS patient IgM autoantigen binding was enhanced. Sera was collected from normal control subjects (controls, n = 20), early (1-12 months after injury) CRPS patients (early CRPS, n = 20), chronic (>12 months after injury) CRPS patients (chronic CRPS, n = 20), and patients who initially had CRPS and pronociceptive serum effects in fracture mice, but were re-evaluated at least a year later and at that point had resolved CRPS and resolved pronociceptive serum effects (resolved CRPS, n = 15). Sera from all 4 groups were tested with IgM binding dot blot studies using 4 recombinant human proteins (keratin 16, histone 3.2, gamma actin, and alpha enolase). These potential autoantigens had been identified as promising candidates from our previous liquid chromatography–mass spectrometry studies in fracture mouse skin. 44 Early CRPS patient IgM binding was increased for all 4 candidate autoantigens, relative to control subject IgM immunoreactivity (A–D). Chronic CRPS IgM binding was increased only for gamma actin proteins, relative to control IgM immunoreactivity (C). Interestingly, the 2 chronic CRPS patients with pronociceptive serum effects in fracture mice (Gi-1 and WK-7, Table 3 ) had the highest IgM immunoreactivity levels to histone 3.2, gamma actin, and alpha enolase of any chronic CRPS patients tested (B–D, red symbols). Resolved CRPS patient IgM binding levels were similar to controls (A–D). A Kruskal-Wallis 1-way ANOVA was performed followed by a Dunn's multiple comparisons test for post hoc contrasts. Data expressed as mean values ± SD. **P < 0.01, and *P < 0.05 vs controls, ##P < 0.01 vs early CRPS. CRPS, complex regional pain syndrome.
3. Results
3.1. Intraperitoneal injections of complex regional pain syndrome serum or IgM had pronociceptive effects in fracture mice
At 3 weeks after right tibia fracture and casting, muMT mice lacking B cells and IgM exhibited unilateral hind paw von Frey allodynia and unweighting the day after cast removal ( Fig. 1 ). Intraperitoneal injection of early (1-12 months after injury) CRPS patient serum (500 μl/1 mL, i.p.) into 3-week postfracture muMT mice caused a gradual increase in hind paw von Frey allodynia and unweighting over the ensuing week that peaked at day 7, and, consistent with the 6 day half-life of IgM, these pronociceptive effects resolved by 2 weeks after injection. The pronociceptive serum effects were restricted to the fracture limb. Similarly, intraperitoneal injection of early CRPS patient IgM (500 μg/1 mL, i.p.) into muMT fracture mice caused a gradual increase in allodynia and unweighting that resolved within 2 weeks. Intraperitoneal injection of serum (500 μl, i.p.) from normal control subjects and IgG (5 mg/1 mL, i.p.) from CRPS patients had no pronociceptive effects. Supplemental Figure 1 (available at http://links.lww.com/PAIN/A925 ) presents the time course of the raw von Frey fiber withdrawal threshold data in the ipsilateral and contralateral hind paws that are presented as side-to-side difference scores in Figure 1A .
The effects of injecting IgM from individual early CRPS patients (n = 5) were evaluated in 3-week postfracture muMT mice, and all 5 CRPS patient IgMs were pronociceptive ( Table 1 ). Furthermore, the individual effects of injecting IgGs from 5 early CRPS patients (n = 5) were evaluated in muMT fracture mice, and none of the IgGs were pronociceptive ( Table 1 ). The CRPS duration ranged from 1 to 8 months in the IgM patient group and from 2 to 5 months in the IgG group, with no evidence of pronociceptive immunoglobulin class switching from IgM to IgG.
Table 1:
Early (1-12 months) CRPS patient IgM/IgG pronociceptive effects in muMT fracture mice.
At 3 weeks after fracture, the muMT mice did not develop warmth and edema in the fracture hind paw, and the injection of CRPS patient serum or IgM had no effect on hind paw temperature or thickness (data not shown).
3.2. Intrathecal or intraplantar complex regional pain syndrome IgM injections were pronociceptive in fracture mice
Intrathecal injection of early (1-12 months after injury) CRPS patient IgM (5 μg/5 μl, i.t.) into the 3-week postfracture muMT mice caused an increase in hind paw von Frey allodynia and unweighting between 0.5 and 6 hours after injection, resolving by 24 hours ( Fig. 2 ). Intrathecal injection of normal control subject IgM had no effect. Supplemental Figure 2 (available at http://links.lww.com/PAIN/A925 ) presents the time course of the raw von Frey fiber withdrawal threshold data in the ipsilateral and contralateral hind paws that are presented as side-to-side difference scores in Figure 2A . Similarly, intraplantar injection of early (1-12 months after injury) CRPS patient IgM (7.8 μg/5 μl, i.pl.) into the fracture limb hind paw of 3-week postfracture muMT mice caused an increase in hind paw von Frey allodynia and unweighting between 1 and 6 hours after injection, resolving by 24 hours ( Fig. 2 ). Intraplantar injection of normal control subject IgM had no effect. The pronociceptive effects of intrathecal or intraplantar CRPS IgM were restricted to the fracture limb, and when nonfractured control mice were injected intrathecally or intraplantarly with CRPS IgM, there were no effects ( Fig. 2 ). Supplemental Figure 3 (available at http://links.lww.com/PAIN/A925 ) presents the time course of the raw von Frey fiber withdrawal threshold data in the ipsilateral and contralateral hind paws that are presented as side-to-side difference scores in Figure 2C of this article. Intraplantar injection of early CRPS patient IgM in muMT fracture mice had no effect on hind paw temperature or thickness (data not shown).
3.3. Patient demographics, clinical presentation, and serum pronociceptive effects
Table 2 presents the demographics and clinical presentation of the normal control subjects (n = 20) evaluated in this study. Half of the subjects were female, and the average age was 49 ± 3 years. None of the 20 normal control subject's sera had pronociceptive effects at 7 days after intraperitoneal injections into muMT fracture mice ( Fig. 3 ).
Table 5:
Repeat CRPS patient serum (n = 10) testing in muMT fracture mice.
Neither the mouse fracture model nor the mechanism of injury for the majority of the CRPS patients in this study involved known nerve damage, but we should acknowledge that the patient population was indeed mixed and that 13% of the CRPS patients in this study were probably CRPS-II patients with injury to the median nerve (WK-2, WK-4, Gi-2, Gi-3, and NC-3218). Table 6 presents the demographics and clinical presentation of orthopedic fracture and/or surgery patients without CRPS (n = 15) at the time of evaluation. The mean time since injury was 2.6 ± 0.5 months at the time of clinical evaluation and serum collection. The average age was 59.5 ± 2.5 years, and the majority (73%) of the subjects were male. The average numerical pain score on an 11-point scale was 0.6 ± 0.2 at the time of serum collection. None of the patients exhibited allodynia, and limb edema was present in 40% of patients. None of the 15 orthopedic trauma no CRPS subject's sera had pronociceptive effects at 7 days after intraperitoneal injections into muMT fracture mice ( Fig. 3 ).
Orthopedic trauma without CRPS patient serum (n = 15) had no effects in muMT fracture mice.
3.4. Increased complex regional pain syndrome IgM binding to autoantigens
Preliminary sera IgM binding dot blot studies were performed using the 9 recombinant human proteins identified as the most promising autoantigen candidates from our previous liquid chromatography–mass spectrometry studies in fracture mouse skin. 44 Only 4 of the candidate autoantigens (keratin 16, histone 3.2, gamma actin, and alpha enolase) exhibited increased binding when probed with CRPS IgM. The other 5 potential autoantigens (GRID2, EEF1A1, beta tubulin, IRAK1, and synaptotagmin) with negative preliminary binding results were dropped from further analyses (data not shown). Early CRPS patient IgM immunoreactivity to keratin 16, histone 3.2, gamma actin, and alpha enolase recombinant proteins was increased relative to control subject IgM immunoreactivity ( Fig. 4 ). Chronic CRPS IgM binding was increased only for gamma actin proteins, relative to control IgM immunoreactivity ( Fig. 4C ). Interestingly, the 2 chronic CRPS patients with pronociceptive serum effects in fracture mice (Gi-1 and WK-7, Table 3 ) had the highest IgM immunoreactivity levels to histone 3.2, gamma actin, and alpha enolase of any chronic CRPS patients tested ( Figs. 4B and C , red symbols). Patients with pronociceptive serum on initial testing in fracture mice who were re-evaluated a year or more later, after resolution of their CRPS symptoms and pronociceptive serum effects (WK-2, WK-11, Gi-3, Gi-9, and Gi-12, Table 5 ), had IgM immunoreactivity levels to keratin 16, histone 3.2, gamma actin, and alpha enolase similar to controls, indicating normalization of antibody titres ( Fig. 4 ).
4. Discussion
Witebsky's criteria for an autoimmune disease include (1) clinical evidence of an autoimmune or inflammatory disorder, (2) demonstration of autoantigens, and (3) reproduction of clinical features in recipient animals by passive transfer of pathogenic antibodies. 42 Clinical evidence suggests that CRPS fulfills the first criteria, with early patients usually exhibiting localized pain, redness, swelling, and warmth. 47 Keratinocytes and mast cells proliferate and express inflammatory cytokines in the CRPS-affected limb. 4,15,21,31 Increased numbers of central memory CD4+ and CD8+ T lymphocytes are observed in CRPS patient blood with activation of proinflammatory signaling, and, similar to many autoimmune diseases, CRPS displays a female preponderance. 9,33
Previously, we performed mass spectroscopy on homogenized fracture mouse paw skin run on 2-D gel and probed with fracture mouse sera to identify keratin 16, histone 3.2, gamma actin, and alpha enolase as potential fracture mouse autoantigens. 44 Furthermore, both fracture mouse and CRPS patient sera exhibited enhanced binding to recombinant keratin 16. 44 Now, we observe increased early CRPS patient serum binding to these autoantigens, relative to normal control sera ( Fig. 4 ). Chronic CRPS sera also exhibited increased binding to gamma actin, but not keratin 16, histone 3.2, or alpha enolase. Resolved CRPS patient sera antigen binding was similar to controls. We did not compare the pattern of autoantibody reactivity in CRPS vs other autoimmune conditions characterized by painful symptoms. These preliminary results support development of multiplex immunoassays for CRPS autoantigens as a potential biomarker screen for the diagnosis of CRPS.
The current study describes the pronociceptive effects of CRPS serum or IgM injections in fracture mice, supporting Witebsky's third criteria of autoimmunity that passive transfer of antibodies from patients can induce clinical features of the disease in recipient animals. Remarkably, every early CRPS patient serum (n = 20) tested in the fracture mice had pronociceptive effects, and none of the sera from normal control subjects (n = 20) or orthopedic trauma patients without CRPS (n = 15) were pronociceptive ( Fig. 3 and Tables 2 , 3 , and 6 ). The CRPS immunoglobulin isotype responsible for serum pronociceptive effects in fracture mice was IgM ( Fig. 1 ), and low doses of intrathecal (5 μg) or intraplantar (7.8 μg) IgM had pronociceptive effects restricted to the fracture limb ( Fig. 2 ), indicating several sites of CRPS antibody pronociceptive action. We did not assess all components of the serum, and some pronociceptive activity may be carried in non-IgM material. However, early CRPS patient IgM, at a dose equivalent to that found in the volume of serum used for all intraperitoneal injections, fully reproduced the magnitude and time course of the pronociceptive effects of early CRPS patient serum in muMT fracture mice ( Fig. 1 ), which does not support the hypothesis that other serum factors contribute to the pronociceptive effects of CRPS serum.
Only 10% of the chronic (>12 months after injury) CRPS patient sera (n = 20) tested in the mouse fracture model had pronociceptive effects ( Fig. 3 and Table 4 ). Possible explanations for the lack of chronic CRPS serum pronociceptive effects in the fracture mice include (1) autoimmunity contributes to early CRPS nociceptive sensitization, but by 12 months after injury, CRPS autoantibodies resolve and central CNS reorganization or other central nociceptive signaling changes are the primary mechanisms supporting CRPS pain and (2) that fracture mice develop antigens for only some of the autoantibodies expressed in CRPS patients. At 12 months after injury, the CRPS antibodies binding to fracture mouse antigens disappear, and in most patients, symptoms improve or resolve, while a minority of CRPS patients chronically express autoantibodies for CRPS antigens that fracture mice either do not express or that are not conserved across mammalian species. This means that despite chronic CRPS patients having persistent pain, their sera would not be pronociceptive in mice, only in the patients themselves, and (3) an IgM to IgG antibody switch occurs after a year in some patients with persistent CRPS, and the IgG dose required to elicit nociceptive effects in muMT fracture mice may be higher than the 5 mg of IgG predicted in the 0.5-mL chronic CRPS serum used in the current study.
The temporal resolution of pronociceptive autoantibody effects over time may explain the spontaneous attenuation or resolution of symptoms that occurs in most CRPS patients within a year of onset. 1,2,37,38,53 We postulate that CRPS patients usually regain immune tolerance over time, and, while still making neoantigens in the injured limb, their adaptive immune system no longer identifies these antigens as “other.” An obvious concern would be that some patients fail to regain immune tolerance, resulting in chronic CRPS.
A previous CRPS antibody transfer study injected IgG collected from chronic (5.3 years' average duration) CRPS patients or healthy controls into hind paw incision mice and observed that CRPS IgG (48 mg over 7 days, n = 30-37 per cohort) caused increased electronic von Frey allodynia, relative to the control IgG, at day 7 after incision. 45 Each CRPS patient serum (n = 6) caused a stronger threshold reduction than their corresponding control; the pooled difference was about 10% absolute threshold reduction, but 2/6 control IgG injections also caused 28% to 32% threshold reductions. A subsequent study demonstrated that 5/7 IgG samples collected from chronic CRPS patients were pronociceptive when injected (8 mg i.p. daily over 3-13 days) in the hind paw incision model, relative to control IgG. The pooled differences with this higher IgG dose were 15% to 32% reduction in nociceptive thresholds, suggesting a dose effect compared with the earlier study. 46 A crucial difference between these hind paw incision studies and the current investigation is the intraperitoneal IgG dosages. The incision studies administered 48 to 104 mg of chronic CRPS IgG given over 4 to 13 injections over 7 to 13 days, and our fracture model study used a single 5-mg injection of early CRPS IgG (equivalent to the total IgG in 0.5 mL of human serum 13 ) Another major difference between these studies is the trauma models used. The hind paw incision model induces transient changes in hind paw inflammation and pain lasting several weeks, while the tibia fracture/cast model induces chronic innate and adaptive immune changes in skin, nerve, and spinal cord with pain behaviors lasting for 5 months. 5,36
The diagnosis of CRPS is based on clinical examination and history, after ruling out other confounding diagnoses, but has only 70% specificity against other limb pain disorders. 3 Previously, proposed serum biomarker assays for CRPS have not been clinically useful, with the best CRPS assay (sensitivity 75% and specificity 100%) requiring a beating cardiomyocyte preparation that has only been used experimentally. 3,24 The CRPS serum passive transfer assay in the muMT fracture mouse had 100% specificity and 100% sensitivity for early (1-12 months after injury) CRPS, compared with normal controls or orthopedic trauma patients without CRPS ( Fig. 3 ), but unfortunately, this bioassay is not available clinically.
The concept of autoantibodies having pronociceptive effects in chronic pain patients is not CRPS specific. Pronociceptive autoantibody effects in mice have also been observed using IgG obtained from rheumatoid arthritis patients positive for anticitrullinated protein antibodies (ACPA+). 52 There is a frequent disconnect between pain and inflammation in rheumatoid arthritis patients, with preclinical patients developing joint pain and ACPA+ sera months to years before signs of joint inflammation and diagnosis. 39,46 Injecting rheumatoid arthritis patient ACPA+ IgG (4 mg) intravenously into normal mice induced hind paw von Frey allodynia that developed over several days and persisted for at least 28 days, consistent with the 21 days half-life of IgG. 52 Injecting control subject IgG or rheumatoid arthritis patient ACPA− IgG had no effect on von Frey thresholds in mice. Furthermore, depleting B cells and IgM with a single infusion of the B-cell antibody rituximab (1000 mg, i.v.) significantly delayed the development of rheumatoid arthritis in ACPA+ subjects in the preclinical stage of arthritis. 11
In summary, one of the proofs of autoimmune disease is the demonstration of pathogenic autoantibodies. The current study has shown that early CRPS patient sera were always pronociceptive in fracture mice, while sera from normal controls or orthopedic trauma patients without CRPS were never pronociceptive. The IgM immunoglobulin isotype mediated the CRPS serum pronociceptive effects in the fracture limb skin and corresponding spinal cord. Collectively, these data support the hypothesis that fracture with cast immobilization in mice can induce the regionally restricted expression of antigens in the fracture limb and corresponding spinal cord that bind with CRPS patient IgM, thus forming an antigen-IgM complex capable of activating complement pronociceptive processes in the fracture limb skin and corresponding cord. 7,23,14 We postulate that similar mechanisms mediate nociceptive sensitization and pain in CRPS patients.
Pursuing autoantibody-mediated pain as a contributor to CRPS could identify new components of the disease process, including novel mechanisms for activation of adaptive immunity and discovery of new treatment approaches for this disabling condition. Based on the current and previous adaptive immunity studies in the fracture model and in preclinical rheumatoid arthritis patients, perhaps the most promising approach would be performing B cell and IgM depletion in early (


Read the rest of this article here